TABLE 2.

Comparison of SUVmax on 68Ga-FAPI-RGD and 68Ga-FAPI-46 PET/CT Images in Primary and Metastatic Lesions

Tumor typenTumor size (cm)TracerPositive lesions (n)SUVmaxTBR
MedianPMedianP
Primary tumors
 NPC12.4 (NA)68Ga-FAPI-RGD25.8NA15.2NA
68Ga-FAPI-4614.57.6
 SCLC14.8 (NA)68Ga-FAPI-RGD9.2NA6.1NA
68Ga-FAPI-465.83.4
 Pancreatic cancer14.3 (NA)68Ga-FAPI-RGD36.3NA51.9NA
68Ga-FAPI-4631.138.9
 Total34.3 (2.4–4.8)68Ga-FAPI-RGD25.8 (9.2–36.3)0.10915.2 (6.1–51.9)0.109
68Ga-FAPI-4614.5 (5.8–31.1)7.6 (3.4–38.9)
Metastases
 Lymph node mets (total)461.1 (0.6–2.8)68Ga-FAPI-RGD4615.5 (4.3–27.1)<0.00113.2 (3.3–38.7)<0.001
68Ga-FAPI-46468.7 (3.3–23.3)8.1 (2.7–18.2)
 Brain mets40.7 (0.4–0.7)68Ga-FAPI-RGD45.8 (4.0–8.3)0.068143.8 (80.0–207.5)0.068
68Ga-FAPI-4643.0 (2.5–4.2)83.7 (65.0–85.0)
 Lung mets151.1 (0.5–1.4)68Ga-FAPI-RGD139.5 (2.0–15.7)0.00418.8 (2.0–39.3)0.003
68Ga-FAPI-46136.4 (1.6–13.3)12.5 (1.6–33.3)
 Liver mets71.1 (0.6–1.4)68Ga-FAPI-RGD76.9 (3.9–16.8)0.0286.3 (3.6–16.8)0.028
68Ga-FAPI-4643.4 (1.8–16.2)3.4 (1.8–16.2)
 Subcutaneous mets50.8 (0.7–0.9)68Ga-FAPI-RGD58.6 (6.6–10.0)0.1387.2 (5.5–10.0)0.08
68Ga-FAPI-4657.2 (6.1–9.0)5.1 (3.6–8.2)
 Bone mets291.2 (0.5–8.2)68Ga-FAPI-RGD2913.7 (6.1–27.6)<0.00114.5 (6.3–27.6)<0.001
68Ga-FAPI-46256.8 (1.2–19.6)6.3 (1.8–21.8)
  • NPC = nasopharyngeal carcinoma; NA = not applicable; SCLC = small lung cancer; mets = metastases.

  • Data in parentheses are ranges.